TB-500 is a short synthetic fragment associated with thymosin beta-4, a 43-amino-acid actin-binding protein present in most mammalian cells.
Key Takeaways
- Thymosin beta-4 sequesters monomeric actin and shapes how cells reorganise their cytoskeleton during migration.
- Animal work has examined dermal wound closure, corneal injury, and cardiac models.
- When you encounter a claim about the fragment, check whether the cited study used the full-length protein.
The parent protein versus the fragment
Thymosin beta-4 sequesters monomeric actin and shapes how cells reorganise their cytoskeleton during migration. TB-500 is a much shorter fragment, and much of the literature people cite for the fragment was actually generated with the full-length protein, which is an important distinction when reading abstracts.
Cell migration as the core hypothesis
The dominant mechanistic story is actin sequestration affecting cell motility. In migration and scratch assays this produces measurable changes, which is why the fragment appears in wound-healing and corneal literature far more often than in metabolic or endocrine work.
For related mechanism work, see delta sleep-inducing peptide.
What has been measured in vivo
Animal work has examined dermal wound closure, corneal injury, and cardiac models. Outcomes are typically structural or histological rather than functional, and the dose ranges used vary widely between groups, making cross-study comparison difficult.
Naming and sourcing problems
TB-500 is a research label rather than a formal nomenclature entry, so products sold under that name differ in sequence and length. Any serious work should confirm the actual sequence by mass spectrometry rather than trusting the label.
Practical reading strategy
When you encounter a claim about the fragment, check whether the cited study used the full-length protein. Conflating the two is the single most common error in secondary summaries of this literature.
Experimental Conditions and Practical Setup
Migration assays are typically run on fibronectin- or collagen-coated plastic in serum-free medium to remove the confounding effect of serum-derived motogens. Because both the full-length protein and the fragment are small and hydrophilic, adsorption to standard tissue-culture plastic is modest, but low-binding plates still give more reproducible closure rates.
Distinguishing the parent protein from the fragment
| Property | Thymosin beta-4 | TB-500 fragment |
|---|---|---|
| Length | 43 residues | Short synthetic fragment |
| Primary literature | Substantial and indexed | Considerably thinner |
| Typical assay | Actin sequestration, migration | Migration and wound closure |
| Nomenclature | Standard gene and protein name | Research label, not formal nomenclature |
Practical Notes for the Bench
- Confirm whether a study used full-length thymosin beta-4 or the fragment.
- Verify the actual sequence rather than relying on the product name.
- Treat migration-assay results as distinct from functional healing endpoints.
Frequently Asked Questions
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is the full 43-amino-acid protein; TB-500 refers to a shorter synthetic fragment associated with it.
Why is the fragment studied in wound models?
Because actin sequestration influences cell migration, which is central to re-epithelialisation and tissue remodelling.
Does TB-500 have an approved medical use?
No approved therapeutic indication exists for the fragment in major regulatory jurisdictions.
Do I need to worry about which vendor’s fragment I buy?
Yes. Because the name is not formally defined, material sold under it differs between suppliers. Confirm the actual sequence by mass spectrometry rather than relying on the label.
Related Reading
- delta sleep-inducing peptide
- thymosin alpha-1
- Selank and Semax research
- PTH analogues bone research
- amylin pramlintide
References & Further Reading
- Faa G et al. Thymosin β(4) and β(10) Expression in Human Organs during Development: A Review. Cells. 2024. PubMed 38994967
- Zeng PM et al. Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids. Stem Cell Reports. 2025. PubMed 40816274
- Bock-Marquette I et al. Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. Int Immunopharmacol. 2023. PubMed 36709593
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- FDA guidance documents on peptide drug products
This article summarises published research practice for laboratory professionals. It is not a guide to human use, and no claim of therapeutic benefit is made or implied.
Reviewed by Dr. Marcus Feld, Molecular Pharmacology, In Vitro Models.